|
|
| No relapse (n = 85) (%) | Relapse (n = 23) (%) | P value |
| Age | <40y | 28 (82.4) | 6 (17.6) | 0.391 |
| 40 to 60y | 47 (74.6) | 16 (25.4) | ||
| >60y | 10 (90.9) | 1 (9.1) | ||
| Menopausal | Premenopausal | 58 (79.5) | 15 (20.5) | 0.784 |
| Postmenopausal | 27 (77.1) | 8 (22.9) | ||
| BMI | <25 | 7 (87.5) | 1 (12.5) | 0.798 |
| 25 to ≤30 | 44 (77.2) | 13 (22.8) | ||
| >30 | 34 (79.7) | 9 (20.9) | ||
| Tumor size | T1 | 10 (100) | 0 (0) | 0.002* |
| T2 | 45 (83.3) | 9 (16.7) | ||
| T3 | 27 (77.1) | 8 (22.9) | ||
| T4 | 3 (33.3) | 6 (66.7) | ||
| LN | N0 | 19 (95.0) | 1 (5.0) | <0.001* |
| N1 | 48 (87.3) | 7 (12.7) | ||
| N2 | 18 (60.0) | 12 (40.0) | ||
| N3 | 0 (0) | 3 (100) | ||
| LVI | Yes | 82 (78.8) | 22 (21.2) | 1.000 |
| No | 3 (75.0) | 1 (25.0) | ||
| K167 (n = 87) | ≤20 | 40 (90.9) | 4 (9.14) | 0.007* |
| >20 | 29 (67.4) | 14 (32.6) | ||
| Tumor grade (n = 107) | II | 33 (80.5) | 8 (19.5) | 0.694 |
| III | 51 (77.3) | 15 (22.7) | ||
| pathology (n = 108) | IDC | 73 (77.7) | 21 (22.3) | 1.000 |
| ILC | 7 (87.5) | 1 (12.5) | ||
| other | 5 (83.4) | 1 (16.6) | ||
| Chemotherapy | FAC | 10 (71.5) | 4 (28.5) | 0.629 |
| AC and Taxol | 75 (79.8) | 19 (20.2) | ||
| Neoadjuvant | 29 (85.3) | 5 (14.7) | 0.391 | |
| Adjuvant | 56 (75.7) | 18 (24.3) | ||
| Radiotherapy | conventional | 44 (78.6) | 12 (22.4) | 1.000 |
| Hypofractionation | 32 (76.2) | 10 (23.8) | ||
| No | 9 (90.0) | 1 (10.0) |